Anti-VEGF | Macular laser | Dexamethasone | ||||
Visits | Treatments | Visits | Treatments | Visits | Treatments | |
Mean total visits and treatment visits (per patient) | ||||||
At 6 months | 5.2 | 3.8 | 2.3 | 1.1 | 3.9 | 1.3 |
At 12 months | 7.9 | 5.1 | 3.2 | 1.2 | 5.6 | 1.5 |
At 18 months | 9.5 | 5.9 | 3.8 | 1.2 | 6.6 | 1.7 |
At 24 months | 10.6 | 6.4 | 4.2 | 1.2 | 7.2 | 1.7 |
At 36 months | 11.7 | 6.9 | 4.6 | 1.2 | 7.8 | 1.7 |
Treatment switching (%) | ||||||
To anti-VEGF | – | 80 (12.6) | 285 (42.2) | |||
To macular laser | 267 (6.8) | – | 63 (9.3) | |||
To dexamethasone | 162 (4.1) | 83 (13.0) | – |
anti-VEGF, anti-vascular endothelial growth factor.